symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
KNSA,16.63,-0.212927,458178,1164733570,0,10.29-20.65,0.29,"Kiniksa Pharmaceuticals, Ltd.",USD,0001730430,BMG5269C1010,G5269C101,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.kiniksa.com,"Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.",Mr. Sanj K. Patel,Healthcare,BM,220,7814399100,Clarendon House,Hamilton,,HM 11,3.73365,17.7236,https://financialmodelingprep.com/image-stock/KNSA.png,2018-05-25,False,False,True,False,False
